Oral calcifediol, the main metabolite of vitamin D3, reduced ICU admission from 50% to 2% among Covid-19 patients.
Published paper
Effect of Calcifediol Treatment and best Available Therapy versus best Available Therapy on Intensive Care Unit Admission and Mortality Among Patients Hospitalized for COVID-19: A Pilot Randomized Clinical study
The vitamin D endocrine system may have a variety of actions on cells and tissues involved in COVID-19 progression.
•
Administration of calcifediol or 25-hydroxyvitamin D to hospitalized COVID-19 patients significantly reduced their need for Intensive Care United admission.
•
Calcifediol seems to be able to reduce severity of the disease.
Participants
76 consecutive patients hospitalized with COVID-19 infection, clinical picture of acute respiratory infection, confirmed by a radiographic pattern of viral pneumonia and by a positive SARS-CoV-2 PCR with CURB65 severity scale (recommending hospital admission in case of total score > 1).
Procedures
All hospitalized patients received as best available therapy the same standard care, (per hospital protocol), of a combination of hydroxychloroquine (400 mg every 12 hours on the first day, and 200 mg every 12 hours for the following 5 days), azithromycin (500 mg orally for 5 days. Eligible patients were allocated at a 2 calcifediol:1 no calcifediol ratio through electronic randomization on the day of admission to take oral calcifediol (0.532 mg), or not. Patients in the calcifediol treatment group continued with oral calcifediol (0.266 mg) on day 3 and 7, and then weekly until discharge or ICU admission. Outcomes of effectiveness included rate of ICU admission and deaths.
Results
Of 50 patients treated with calcifediol, one required admission to the ICU (2%), while of 26 untreated patients, 13 required admission (50%) p value X2 Fischer test p < 0.001. Univariate Risk Estimate Odds Ratio for ICU in patients with Calcifediol treatment versus without Calcifediol treatment: 0.02 (95%CI 0.002-0.17). Multivariate Risk Estimate Odds Ratio for ICU in patients with Calcifediol treatment vs Without Calcifediol treatment ICU (adjusting by Hypertension and T2DM): 0.03 (95%CI: 0.003-0.25). Of the patients treated with calcifediol, none died, and all were discharged, without complications. The 13 patients not treated with calcifediol, who were not admitted to the ICU, were discharged. Of the 13 patients admitted to the ICU, two died and the remaining 11 were discharged.
Conclusion
Our pilot study demonstrated that administration of a high dose of Calcifediol or 25-hydroxyvitamin D, a main metabolite of vitamin D endocrine system, significantly reduced the need for ICU treatment of patients requiring hospitalization due to proven COVID-19. Calcifediol seems to be able to reduce severity of the disease, but larger trials with groups properly matched will be required to show a definitive answer.
引子：
这是第一篇正式临床研究，证明使用维生素D可以有效地减缓新冠病情。
羟奎加阿奇霉：26人，有一半的患者进了ICU，其中二人不治。
再加上VD：50人里，只有一位进去了，全部治愈。
这个不是奇迹，是什么！
那个“XXXX望", 有这效果么？
花点时间，认真看看，学点本事，也许救命。
News report
https://medium.com/@shinjieyong/the-first-clinical-trial-to-support-vitamin-d-therapy-for-covid-19-906a9d907468
Oral calcifediol, the main metabolite of vitamin D3, reduced ICU admission from 50% to 2% among Covid-19 patients.
Published paper
Effect of Calcifediol Treatment and best Available Therapy versus best Available Therapy on Intensive Care Unit Admission and Mortality Among Patients Hospitalized for COVID-19: A Pilot Randomized Clinical study
https://www.sciencedirect.com/science/article/pii/S0960076020302764?via%3Dihub#bib0100
Highlights
•
The vitamin D endocrine system may have a variety of actions on cells and tissues involved in COVID-19 progression.
•
Administration of calcifediol or 25-hydroxyvitamin D to hospitalized COVID-19 patients significantly reduced their need for Intensive Care United admission.
•
Calcifediol seems to be able to reduce severity of the disease.
Participants
76 consecutive patients hospitalized with COVID-19 infection, clinical picture of acute respiratory infection, confirmed by a radiographic pattern of viral pneumonia and by a positive SARS-CoV-2 PCR with CURB65 severity scale (recommending hospital admission in case of total score > 1).
Procedures
All hospitalized patients received as best available therapy the same standard care, (per hospital protocol), of a combination of hydroxychloroquine (400 mg every 12 hours on the first day, and 200 mg every 12 hours for the following 5 days), azithromycin (500 mg orally for 5 days. Eligible patients were allocated at a 2 calcifediol:1 no calcifediol ratio through electronic randomization on the day of admission to take oral calcifediol (0.532 mg), or not. Patients in the calcifediol treatment group continued with oral calcifediol (0.266 mg) on day 3 and 7, and then weekly until discharge or ICU admission. Outcomes of effectiveness included rate of ICU admission and deaths.
Results
Of 50 patients treated with calcifediol, one required admission to the ICU (2%), while of 26 untreated patients, 13 required admission (50%) p value X2 Fischer test p < 0.001. Univariate Risk Estimate Odds Ratio for ICU in patients with Calcifediol treatment versus without Calcifediol treatment: 0.02 (95%CI 0.002-0.17). Multivariate Risk Estimate Odds Ratio for ICU in patients with Calcifediol treatment vs Without Calcifediol treatment ICU (adjusting by Hypertension and T2DM): 0.03 (95%CI: 0.003-0.25). Of the patients treated with calcifediol, none died, and all were discharged, without complications. The 13 patients not treated with calcifediol, who were not admitted to the ICU, were discharged. Of the 13 patients admitted to the ICU, two died and the remaining 11 were discharged.
Conclusion
Our pilot study demonstrated that administration of a high dose of Calcifediol or 25-hydroxyvitamin D, a main metabolite of vitamin D endocrine system, significantly reduced the need for ICU treatment of patients requiring hospitalization due to proven COVID-19. Calcifediol seems to be able to reduce severity of the disease, but larger trials with groups properly matched will be required to show a definitive answer.
附注
calcifediol (0.532 mg) 大约合20000IU。如果家里有五千IU胶丸，首日服四粒，在第三天和第七天各服两丸。
一共就八粒VD胶丸，也许帮你逃过一劫。
俺家里现在只有2000IU的，得赶紧去抢一甁5000的。不过一盘菜价而已。
再啰嗦一句，D3经肝脏再经肾脏转化成calcifediol，后者直接作用于受体，……。这个转化过程可能需要数日，故有研究说calcifediol效果比较好。可惜是处方药，买不到。
俺家里现在只有2000IU的，得赶紧去抢一甁5000的。
TBz: 一共需要八粒5000的VD胶丸，如果用2000IU的，20粒就好了。我们常吃的维生素D3并非他们在试验中用的25(OH)D3. 后者提高体内25(OH)D3的能力大概是前者的三倍。
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289092/